A note from Josh Hardman… It’s been over two years since I launched Psilocybin Alpha. As I mentioned in our 2021 Year in Review, I have recently been reflecting on just how inappropriate the name Psilocybin Alpha has become. When I started writing about psychedelics, psilocybin was at the forefront of clinical research into the ‘true’ psychedelics and the subject of early investor interest.


Previous articlePT314 – Daniel McQueen, MA – Vital Psychedelic Conversations
Next articlePT315 – Dr. Dominique Morisano – From Research to Reality: Planning a Global Psychedelic Summit